| | | | | | | |
 | GILEAD SCIENCES, INC. | 0.80% | 7.77% | -13.12% | -7.07% | -5.40% | 79 122 |
| VERTEX PHARMACEUTICALS | 3.19% | 11.20% | 33.22% | 50.54% | 64.67% | 74 821 |
| REGENERON PHARMACEUTICALS, INC. | 0.84% | 5.43% | -3.01% | 11.25% | 100.76% | 65 993 |
 | WUXI APPTEC CO., LTD. | 8.69% | 4.87% | -13.42% | -34.44% | 177.91% | 44 742 |
| BIONTECH SE | 1.32% | 7.11% | -48.01% | -41.73% | --.--% | 32 574 |
 | GENMAB A/S | 3.19% | 12.36% | -15.13% | -14.48% | 91.10% | 20 738 |
 | ARGENX SE | -1.09% | 1.60% | 6.66% | 26.33% | 179.55% | 19 381 |
| BEIGENE, LTD. | 13.95% | 34.70% | -34.30% | -51.01% | 42.78% | 18 382 |
| NEUROCRINE BIOSCIENCES, INC. | 0.86% | 5.32% | 15.35% | -2.04% | 22.94% | 9 389 |
| LEGEND BIOTECH CORPORATION | 3.44% | 14.34% | 13.41% | 31.79% | --.--% | 8 153 |
| EXELIXIS, INC. | 4.17% | 19.72% | 21.55% | -5.12% | 6.57% | 7 127 |
| SAREPTA THERAPEUTICS, INC. | 4.73% | 12.32% | -16.47% | -6.44% | -41.39% | 6 582 |
| HALOZYME THERAPEUTICS, INC. | 0.21% | 6.25% | 16.64% | 3.90% | 187.38% | 6 462 |
| INTRA-CELLULAR THERAPIES, INC. | -2.75% | 1.24% | 6.27% | 34.02% | 340.73% | 5 246 |
| ASCENDIS PHARMA A/S | -0.42% | 8.54% | -32.29% | -35.10% | -16.34% | 5 084 |
| | | | | | | |
| | Durchschnitt | 2.74% | 10.18% | -4.18% | -2.64% | 88.56% | |
| | Gewichteter Durchschnitt nach Marktkapitalisierung | 2.90% | 9.08% | -3.61% | 1.29% | 77.35% | |
English (USA)
English (UK)
English (Canada)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Bericht
